Should I Buy APLS? APLS 2026 Analysis

Should You Buy Apellis Pharmaceuticals Inc (APLS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Buy

Latest Price

23.050

1 Day change

-0.09%

52 Week Range

30.600

Analysis Updated At

2026/01/28

Buy now for a long-term position. APLS has a fresh FDA-driven growth catalyst (Empaveli in C3G/IC-MPGN), supportive options sentiment (call-heavy positioning), and hedge fund accumulation. While the chart is not in a clean uptrend yet, downside appears more defined around the ~21.15 pivot/support area, and the SwingMax entry signal (2026-01-26) supports taking the trade even after a small move. Key near-term level to watch is ~22.62 resistance; a hold above it would improve trend confirmation.

Technical Analysis

Pre-market price is 22.37 (+2.48%), trading above the pivot (21.154) and below the first resistance (R1 22.619), which places the stock in a near-term decision zone. - Trend/Momentum: MACD histogram is negative (-0.176) but negatively contracting, suggesting bearish momentum is fading (early stabilization rather than a confirmed uptrend). - RSI: RSI(6) at 46.94 is neutral, consistent with consolidation. - Moving Averages: Converging moving averages indicates a transition phase (no strong trend; breakout/breakdown risk). - Levels: Support = 21.154 (pivot), then 19.69 (S1). Resistance = 22.619 (R1), then 23.523 (R2). With price at 22.37, upside confirmation improves on a push/hold above ~22.62; downside risk increases if it loses ~21.15. - Intellectia Proprietary Trading Signals: **Intellectia Proprietary Trading Signals** - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): Entry signal triggered on 2026-01-26; price change since signal is +1.91%, and it still supports an active entry for an investor who does not want to wait for an “ideal” pullback. - Pattern-based probability (from similar candlestick setups): Slightly negative bias over 1-week to 1-month (-0.52% next week; -1.01% next month). This reinforces that the stock is not yet technically “easy,” but catalysts/options/flows can override this if demand continues.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options positioning is notably bullish: - Open Interest Put-Call Ratio 0.22: very call-skewed open interest, implying bullish longer positioning/hedges favor upside. - Option Volume Put-Call Ratio 0.43: calls also leading in daily sentiment. - Activity: Today’s volume is ~7.24x the 30-day average (elevated attention/positioning), and today vs open-interest averages are also extremely high, suggesting fresh positioning. - Volatility: 30D IV ~64.35 vs historical vol ~122.52 (HV higher than IV). The market is pricing sizable moves but not as extreme as recent realized volatility; this often happens after sharp swings and can precede another move if a catalyst hits. Overall read: options sentiment is risk-on/bullish, consistent with investors positioning for follow-through after the FDA/launch news.

Technical Summary

Sell

Buy

Positive Catalysts

2) Launch traction narrative: BofA notes 267 new patient start forms post-approval and views the launch trajectory as strong, implying potential estimate upside.
4) Flows: Hedge funds are buying, with reported buying amount up ~132.99% over the last quarter.

Neutral/Negative Catalysts

1) Insider selling: insiders are selling, with selling amount reported up ~2370.20% over the last month (a meaningful sentiment/overhang signal).
2) Syfovre growth concerns: multiple analysts have referenced flattish/challenged Syfovre revenue and a “show-me” setup for future growth.
3) Slower-than-expected ramp risk: Wells Fargo noted a slower ramp in C3G/IC-MPGN expectations and cut longer-term estimates (even while staying Overweight).
4) High realized volatility: HV is very high, which can translate into sharp drawdowns even during fundamentally positive periods.
5) Event risk ahead: Next earnings (QDEC 2025) on 2026-02-26 pre-market (a major catalyst that can reprice the stock quickly depending on guidance and launch updates).

Financial Performance

Latest reported quarter: 2025/Q3. - Revenue: 458.578M, up +132.98% YoY (strong top-line growth). - Profitability: Net income 215.715M, down -475.52% YoY; EPS 1.66, down -460.87% YoY (earnings volatility/quality is not consistent despite revenue strength). - Gross margin: 94.65%, up +14.10% YoY (very strong margin profile). Overall: revenue growth and gross margin are strong, but earnings metrics swung sharply lower YoY—investors are paying for growth/trajectory rather than smooth profitability right now.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: mixed but improving at the margin in January. - Positive changes: BofA upgraded to Buy (PT $28) on 2026-01-21, citing underappreciated Empaveli commercial potential and strong early demand signals. Barclays initiated at Equal Weight with PT $24 (neutral stance but constructive biotech backdrop). - Cautionary notes: Wells Fargo trimmed PT to $26 (still Overweight) due to slower ramp expectations; multiple firms in late 2025 lowered price targets (JPM $36, Stifel $48, TD Cowen/Wainwright/Citi $45) reflecting slower Syfovre momentum and post-earnings resets. Wall Street pros view (summary): - Pros: Empaveli approval and early launch indicators can drive multi-year growth; some analysts see valuation not reflecting new indication potential. - Cons: Syfovre growth has been a recurring concern; ramp uncertainty is keeping several firms cautious/neutral, and price targets have generally been cut over recent months. Influential figures / politicians: No recent congress trading data available in the last 90 days, and no politician activity was provided.

14 Analyst Rating

Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 43.25 USD with a low forecast of 22 USD and a high forecast of 117.8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

9 Buy

5 Hold

0 Sell

Moderate Buy

Current: 23.070

Low

Averages

43.25

High

117.8

Current: 23.070

Low

Averages

43.25

High

117.8

Barclays

Equal Weight

initiated

$24

AI Analysis

2026-01-27

New

Reason

Barclays

Price Target

$24

AI Analysis

2026-01-27

New

initiated

Equal Weight

Reason

Barclays initiated coverage of Apellis with an Equal Weight rating and $24 price target. Barclays initiated coverage of 12 biotech stocks and assumed coverage of 11 with a positive view of the industry. The analyst likes the setup for the group in 2026. Many biotech stocks remain undervalued, the analyst tells investors in a research note. The firm expects continued mergers and acquisitions, "strong" underlying fundamentals, and less of a focus on drug pricing to act as "significant tailwinds."

BofA

Tazeen Ahmad

Neutral -> Buy

upgrade

$28

2026-01-21

Reason

BofA

Tazeen Ahmad

Price Target

$28

2026-01-21

upgrade

Neutral -> Buy

Reason

BofA analyst Tazeen Ahmad upgraded Apellis to Buy from Neutral with an unchanged price target of $28. The firm believes current valuation levels underappreciate the commercial potential of Empaveli in new rare kidney disease indications. Since approval in late July, Apellis has received 267 new patient start forms for Empaveli, representing 5% penetration of the 5,000 U.S. patient population, the analyst tells investors in a research note. BofA is "encouraged" by the "strong launch trajectory" and see rooms for continued estimate upside.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for APLS

Unlock Now

APLS Should I Buy

APLS Should I Buy

Should You Buy Apellis Pharmaceuticals Inc (APLS) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch